Uncategorized-EN

  USA: GSI – GIST Support International Back to members Organisation Profile GIST Support International (GSI) is an all-volunteer group of patients with gastrointestinal stromal tumor (GIST), family members, and interested professionals.  Our e-mail listserv includes over 1400 subscribers who form an online community to share information about GIST treatment and to support each other in living with…

USA: Chordoma Foundation Back to members Organisation Profile Chordoma is a rare cancer that grows in the bones of the skull and spine. It can affect people of all ages and is diagnosed in just one in one million people per year. Chordomas are complicated tumors to treat properly and often regrow after treatment. Currently,…

  USA: Chondrosarcoma Foundation Back to members Organisation Profile The purpose of CS Foundation is to educate the public about Chondrosarcoma; support and advocate for patients and families that are suffering from this disease, and advocate to improve the treatment and care for these patients. CS Foundation also strives to advocate and promote positive changes…

UK: The Boom Foundation   Back to members Organisation Profile ​ The Boom Foundation is the only charity in Northern Ireland dedicated to supporting patients suffering from sarcoma cancer.  There are over 100 new patients diagnosed with sarcoma each year in NI, many of whom are children. In its first year (April 2013 – April…

A multicenter, randomized, phase III study to assess the efficacy and safety of intratumorally administered INT230-6 in locally recurrent, inoperable or metastatic soft tissue sarcomas. Agents: INT230-6 Phase III Status Active, not recruiting Sponsor Intensity Therapeutics, Inc.   Further information: https://www.clinicaltrials.gov/study/NCT06263231   WHO is the trial for? Adult patients with the following subtypes of soft…

  Trial name: IAG933 in Advanced Solid Tumors incl. EHE Agents: IAG933 Phase I Status Active,but not recruiting Sponsor Novartis Pharmaceuticals   This is a phase I, open-label, multi-center study of IAG933 to assesss the safety and tolerability as well as anti-tumor activity in certain patient populations. This includes patients with epithelioid hemangioendothelioma (EHE). Further…

  Trial name: ADC AVA6000 in Advanced Solid Tumors Agents: AVA6000 Phase I Status Recruiting Sponsor Avacta Life Sciences Ltd   This phase I study evaluates the safety, tolerability, pharmacokinetics (PK) and early efficacy of AVA6000 in patients with locally advanced and/or metastatic solid tumours incl. soft tissue sarcomas. Further information can be found on…